patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_667218 | REC_0005401 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 16.4 | 78 | male | 2 | 15 | 3.2 | 6 | osimertinib 80 mg daily | 8.2 | false | MSI-H | 2026-03-15T05:35:58.181400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381279 | REC_0005402 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 10.7 | 67 | female | 0 | 9 | 4.4 | 2 | osimertinib 80 mg daily | 23.2 | true | MSS | 2026-03-15T05:35:58.181632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199856 | REC_0005403 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 3.1 | 58 | male | 0 | 34 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.6 | true | MSS | 2026-03-15T05:35:58.181866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993815 | REC_0005404 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 13.2 | 77 | female | 0 | 19 | 4.3 | 2 | alectinib 600 mg BID | 14 | false | MSI-H | 2026-03-15T05:35:58.182100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262268 | REC_0005405 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 9.9 | 81 | female | 2 | 11 | 5.3 | 2 | osimertinib 80 mg daily | 17.3 | true | MSS | 2026-03-15T05:35:58.182328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626097 | REC_0005406 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 17.6 | 69 | female | 0 | 10 | 6 | 4 | osimertinib 80 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:35:58.182559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829271 | REC_0005407 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 9.3 | 76 | female | 2 | 0 | 6.9 | 6 | sotorasib 960 mg daily | 6.4 | false | MSS | 2026-03-15T05:35:58.182786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844325 | REC_0005408 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 13.3 | 62 | female | 1 | 16 | 5.1 | 3 | alectinib 600 mg BID | 9 | true | MSI-H | 2026-03-15T05:35:58.183020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137041 | REC_0005409 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 2.9 | 60 | male | 0 | 13 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.9 | true | MSS | 2026-03-15T05:35:58.183335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285211 | REC_0005410 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13.8 | 70 | female | 2 | 19 | 3.6 | 8 | entrectinib 600 mg daily | 5.9 | true | MSI-H | 2026-03-15T05:35:58.183576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128838 | REC_0005411 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.2 | 56 | female | 1 | 7 | 6.1 | 4 | alectinib 600 mg BID | 4.5 | false | MSI-H | 2026-03-15T05:35:58.183815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616541 | REC_0005412 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 10.2 | 62 | male | 1 | 15 | 4.3 | 2 | osimertinib 80 mg daily | 16 | false | MSS | 2026-03-15T05:35:58.184052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181230 | REC_0005413 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 14.2 | 68 | female | 0 | 11 | 4.2 | 2 | osimertinib 80 mg daily | 21.3 | false | MSI-H | 2026-03-15T05:35:58.184333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383044 | REC_0005414 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.2 | 64 | female | 0 | 48 | 4 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.4 | false | MSS | 2026-03-15T05:35:58.184571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152504 | REC_0005415 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 7.8 | 69 | female | 0 | 12 | 5.8 | 2 | pembrolizumab 200 mg q3w | 23.5 | false | MSS | 2026-03-15T05:35:58.184806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184460 | REC_0005416 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 11.9 | 80 | female | 2 | 19 | 5.4 | 1 | osimertinib 80 mg daily | 27.6 | false | MSS | 2026-03-15T05:35:58.185038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736629 | REC_0005417 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 5.8 | 70 | female | 2 | 16 | 5.7 | 2 | pembrolizumab 200 mg q3w | 28.8 | true | MSS | 2026-03-15T05:35:58.185269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303598 | REC_0005418 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 5 | 75 | female | 1 | 4 | 5.4 | 5 | sotorasib 960 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:58.185499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547540 | REC_0005419 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 21 | 16.8 | 70 | male | 0 | 3 | 5.5 | 0 | entrectinib 600 mg daily | 28.4 | false | MSI-H | 2026-03-15T05:35:58.185732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494035 | REC_0005420 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 24 | 11.9 | 67 | female | 0 | 19 | 4.7 | 0 | entrectinib 600 mg daily | 27.3 | false | MSS | 2026-03-15T05:35:58.185968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643803 | REC_0005421 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 13 | 67 | female | 0 | 23 | 5 | 7 | entrectinib 600 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:35:58.186199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497261 | REC_0005422 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 11.9 | 75 | female | 2 | 16 | 4 | 1 | osimertinib 80 mg daily | 17.3 | false | MSI-H | 2026-03-15T05:35:58.186477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426462 | REC_0005423 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 2.4 | 73 | female | 1 | 33 | 4.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:35:58.186711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728239 | REC_0005424 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.9 | 72 | female | 1 | 8 | 6 | 7 | osimertinib 80 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:58.186943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279894 | REC_0005425 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12.2 | 66 | female | 0 | 11 | 5.5 | 8 | osimertinib 80 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:58.187175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673819 | REC_0005426 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 15.2 | 83 | male | 1 | 19 | 6.2 | 8 | alectinib 600 mg BID | 16.3 | false | MSI-H | 2026-03-15T05:35:58.187410+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660086 | REC_0005427 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 14.4 | 78 | female | 1 | 20 | 6.4 | 1 | osimertinib 80 mg daily | 20.7 | true | MSS | 2026-03-15T05:35:58.187641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405693 | REC_0005428 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 3.8 | 69 | female | 0 | 64 | 8.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.5 | false | MSS | 2026-03-15T05:35:58.187868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449328 | REC_0005429 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 7.6 | 61 | female | 0 | 65 | 7 | 2 | carboplatin + paclitaxel + pembrolizumab | 24 | true | MSS | 2026-03-15T05:35:58.188179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127584 | REC_0005430 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 12.9 | 71 | female | 2 | 11 | 3.7 | 0 | osimertinib 80 mg daily | 15.8 | true | MSI-H | 2026-03-15T05:35:58.188422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924918 | REC_0005431 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 5.1 | 65 | female | 1 | 18 | 8.4 | 0 | osimertinib 80 mg daily | 44 | false | MSS | 2026-03-15T05:35:58.188656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300511 | REC_0005432 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.7 | 56 | female | 1 | 24 | 5.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:35:58.188885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112355 | REC_0005433 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12 | 59 | female | 0 | 5 | 6.1 | 6 | osimertinib 80 mg daily | 14.6 | false | MSS | 2026-03-15T05:35:58.189123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768436 | REC_0005434 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 16.1 | 78 | female | 1 | 9 | 5.3 | 5 | entrectinib 600 mg daily | 9.2 | false | MSI-H | 2026-03-15T05:35:58.189352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569436 | REC_0005435 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 8.4 | 56 | male | 1 | 7 | 4.7 | 1 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:58.189637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136284 | REC_0005436 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 13.9 | 38 | male | 0 | 11 | 6.8 | 5 | osimertinib 80 mg daily | 19.1 | false | MSS | 2026-03-15T05:35:58.189871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594263 | REC_0005437 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 5.8 | 58 | female | 0 | 90 | 7.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.1 | false | MSS | 2026-03-15T05:35:58.190105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855299 | REC_0005438 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.3 | 75 | female | 3 | 4 | 5 | 5 | osimertinib 80 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:35:58.190338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361937 | REC_0005439 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 17 | 5.6 | 59 | female | 0 | 25 | 7.7 | 4 | pembrolizumab 200 mg q3w | 13.4 | true | MSS | 2026-03-15T05:35:58.190572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597416 | REC_0005440 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 3.1 | 82 | female | 0 | 56 | 4 | 2 | carboplatin + paclitaxel + pembrolizumab | 29.5 | false | MSS | 2026-03-15T05:35:58.190806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434284 | REC_0005441 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 7.1 | 74 | female | 2 | 54 | 5.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 13 | false | MSS | 2026-03-15T05:35:58.191033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273911 | REC_0005442 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 7.6 | 70 | female | 1 | 27 | 6.2 | 2 | pembrolizumab 200 mg q3w | 24.4 | false | MSS | 2026-03-15T05:35:58.191259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631934 | REC_0005443 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 9.8 | 80 | male | 0 | 16 | 7.4 | 6 | entrectinib 600 mg daily | 18.5 | false | MSS | 2026-03-15T05:35:58.191492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554031 | REC_0005444 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12.8 | 77 | female | 2 | 26 | 6 | 1 | sotorasib 960 mg daily | 18.2 | false | MSS | 2026-03-15T05:35:58.191725+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320532 | REC_0005445 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 9.3 | 69 | female | 0 | 15 | 4.1 | 3 | alectinib 600 mg BID | 6.1 | false | MSS | 2026-03-15T05:35:58.191952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680379 | REC_0005446 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 8.5 | 48 | male | 0 | 10 | 8.4 | 1 | alectinib 600 mg BID | 21.4 | true | MSS | 2026-03-15T05:35:58.192220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329144 | REC_0005447 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 10.8 | 72 | female | 1 | 20 | 5.6 | 1 | osimertinib 80 mg daily | 17.3 | true | MSS | 2026-03-15T05:35:58.192461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857000 | REC_0005448 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 10.3 | 60 | female | 1 | 16 | 7.2 | 1 | alectinib 600 mg BID | 21.2 | false | MSS | 2026-03-15T05:35:58.192748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567137 | REC_0005449 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 10.3 | 77 | female | 2 | 24 | 5.8 | 7 | sotorasib 960 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:58.192987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241517 | REC_0005450 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.2 | 70 | female | 1 | 14 | 3.6 | 2 | entrectinib 600 mg daily | 11.6 | false | MSI-H | 2026-03-15T05:35:58.193220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577775 | REC_0005451 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 15 | 11.9 | 78 | female | 1 | 13 | 8.4 | 2 | sotorasib 960 mg daily | 14.4 | true | MSS | 2026-03-15T05:35:58.193453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181638 | REC_0005452 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 3 | 73 | female | 1 | 53 | 6.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 13.9 | false | MSS | 2026-03-15T05:35:58.193680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603667 | REC_0005453 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 15.8 | 64 | male | 0 | 20 | 4.9 | 7 | osimertinib 80 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:58.193916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932001 | REC_0005454 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 8.1 | 78 | female | 2 | 11 | 5.2 | 5 | alectinib 600 mg BID | 14.2 | false | MSS | 2026-03-15T05:35:58.194142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764636 | REC_0005455 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.9 | 69 | female | 1 | 35 | 6.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:35:58.194370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517299 | REC_0005456 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 17.7 | 75 | female | 1 | 12 | 4.3 | 2 | entrectinib 600 mg daily | 29.1 | true | MSS | 2026-03-15T05:35:58.194602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747504 | REC_0005457 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 19 | 7 | 61 | male | 0 | 10 | 5.1 | 0 | osimertinib 80 mg daily | 61 | false | MSS | 2026-03-15T05:35:58.194835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825673 | REC_0005458 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 10.1 | 55 | female | 0 | 17 | 6.5 | 7 | osimertinib 80 mg daily | 12.9 | false | MSI-H | 2026-03-15T05:35:58.195067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545614 | REC_0005459 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 3.1 | 84 | female | 1 | 34 | 4.5 | 4 | pembrolizumab 200 mg q3w | 6.7 | true | MSS | 2026-03-15T05:35:58.195295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688644 | REC_0005460 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 14.4 | 75 | female | 1 | 17 | 4.7 | 4 | sotorasib 960 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:58.195525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810932 | REC_0005461 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 14.5 | 61 | female | 0 | 20 | 3.1 | 5 | osimertinib 80 mg daily | 23.5 | false | MSS | 2026-03-15T05:35:58.195805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798977 | REC_0005462 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 17.9 | 62 | male | 0 | 18 | 7.5 | 5 | alectinib 600 mg BID | 16.2 | false | MSS | 2026-03-15T05:35:58.196046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537765 | REC_0005463 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.2 | 60 | female | 0 | 13 | 6.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.5 | false | MSS | 2026-03-15T05:35:58.196440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268145 | REC_0005464 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 25 | 12.3 | 90 | female | 2 | 16 | 5 | 0 | entrectinib 600 mg daily | 38 | true | MSS | 2026-03-15T05:35:58.196681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848833 | REC_0005465 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 13.3 | 60 | male | 0 | 15 | 5 | 9 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:58.196917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368738 | REC_0005466 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 10.2 | 67 | female | 0 | 11 | 6.1 | 3 | entrectinib 600 mg daily | 17.5 | true | MSI-H | 2026-03-15T05:35:58.197150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247982 | REC_0005467 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 16.5 | 81 | female | 2 | 6 | 3.4 | 5 | alectinib 600 mg BID | 10.5 | false | MSI-H | 2026-03-15T05:35:58.197386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671762 | REC_0005468 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 15 | 7.9 | 66 | female | 0 | 33 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.8 | false | MSS | 2026-03-15T05:35:58.197634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155822 | REC_0005469 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 13.7 | 81 | female | 2 | 10 | 4.9 | 5 | alectinib 600 mg BID | 7 | false | MSS | 2026-03-15T05:35:58.197891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264339 | REC_0005470 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 13.8 | 67 | male | 0 | 25 | 6.7 | 7 | sotorasib 960 mg daily | 12.7 | false | MSI-H | 2026-03-15T05:35:58.198155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393059 | REC_0005471 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 18.4 | 70 | female | 2 | 22 | 5.7 | 2 | entrectinib 600 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:35:58.198417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452952 | REC_0005472 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 24 | 4.6 | 62 | male | 1 | 34 | 5.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 22.2 | false | MSS | 2026-03-15T05:35:58.198680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679861 | REC_0005473 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.2 | 77 | female | 3 | 0 | 6.9 | 4 | osimertinib 80 mg daily | 5.4 | false | MSI-H | 2026-03-15T05:35:58.198949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943846 | REC_0005474 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 17.7 | 58 | female | 1 | 15 | 7.1 | 6 | osimertinib 80 mg daily | 17.4 | true | MSI-H | 2026-03-15T05:35:58.199325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540237 | REC_0005475 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.9 | 58 | male | 1 | 53 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 8 | false | MSS | 2026-03-15T05:35:58.199581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875066 | REC_0005476 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 10.8 | 63 | male | 0 | 16 | 5 | 1 | osimertinib 80 mg daily | 13.6 | false | MSS | 2026-03-15T05:35:58.199820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700587 | REC_0005477 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 10.9 | 72 | female | 1 | 6 | 4.7 | 3 | entrectinib 600 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:58.200052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556569 | REC_0005478 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 9.4 | 64 | male | 0 | 14 | 7.5 | 5 | entrectinib 600 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:58.200469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532097 | REC_0005479 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 10.6 | 58 | female | 1 | 18 | 6.2 | 9 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:35:58.200721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148319 | REC_0005480 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 7.7 | 55 | male | 1 | 23 | 5 | 2 | alectinib 600 mg BID | 22.5 | true | MSS | 2026-03-15T05:35:58.200962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118426 | REC_0005481 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 13.6 | 72 | female | 1 | 17 | 5.3 | 4 | entrectinib 600 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:58.201198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378503 | REC_0005482 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 13.5 | 72 | female | 1 | 0 | 5.3 | 8 | osimertinib 80 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:58.201435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649518 | REC_0005483 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 20 | 13.7 | 81 | female | 3 | 9 | 2 | 0 | alectinib 600 mg BID | 39.5 | true | MSI-H | 2026-03-15T05:35:58.201675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695615 | REC_0005484 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.2 | 78 | female | 1 | 17 | 5.8 | 4 | alectinib 600 mg BID | 14.1 | false | MSI-H | 2026-03-15T05:35:58.201912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535556 | REC_0005485 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.8 | 71 | female | 2 | 8 | 6.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 11 | true | MSS | 2026-03-15T05:35:58.202142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679289 | REC_0005486 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 4.8 | 64 | male | 1 | 20 | 3.1 | 5 | sotorasib 960 mg daily | 14.6 | false | MSS | 2026-03-15T05:35:58.202377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491045 | REC_0005487 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 9.2 | 79 | male | 1 | 17 | 7.3 | 1 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:58.202694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155107 | REC_0005488 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.8 | 76 | female | 1 | 2 | 6.2 | 5 | alectinib 600 mg BID | 18.1 | false | MSS | 2026-03-15T05:35:58.202932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218977 | REC_0005489 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 1.5 | 70 | female | 2 | 10 | 7.3 | 4 | alectinib 600 mg BID | 8 | false | MSS | 2026-03-15T05:35:58.203167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354429 | REC_0005490 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.3 | 68 | female | 1 | 13 | 3.1 | 4 | osimertinib 80 mg daily | 11.3 | false | MSI-H | 2026-03-15T05:35:58.203399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597799 | REC_0005491 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.2 | 57 | male | 0 | 66 | 5.2 | 5 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:58.203634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648109 | REC_0005492 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 10.3 | 51 | female | 0 | 14 | 3.6 | 7 | osimertinib 80 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:58.203873+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286661 | REC_0005493 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.7 | 65 | female | 1 | 29 | 5.3 | 8 | pembrolizumab 200 mg q3w | 11.8 | false | MSS | 2026-03-15T05:35:58.204280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926634 | REC_0005494 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 10 | 77 | female | 1 | 20 | 6.3 | 5 | osimertinib 80 mg daily | 9.4 | true | MSS | 2026-03-15T05:35:58.204540+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334483 | REC_0005495 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 10.2 | 83 | female | 1 | 20 | 6.1 | 8 | entrectinib 600 mg daily | 9.9 | false | MSI-H | 2026-03-15T05:35:58.204778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707529 | REC_0005496 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 17.2 | 73 | female | 1 | 9 | 2.2 | 2 | entrectinib 600 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:58.205013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244619 | REC_0005497 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 5.3 | 73 | female | 2 | 18 | 4.9 | 1 | osimertinib 80 mg daily | 19.5 | true | MSS | 2026-03-15T05:35:58.205245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977530 | REC_0005498 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 3.3 | 62 | male | 1 | 5 | 4 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.3 | false | MSS | 2026-03-15T05:35:58.205481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556192 | REC_0005499 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 13.2 | 72 | male | 1 | 17 | 6 | 1 | sotorasib 960 mg daily | 21.7 | true | MSI-H | 2026-03-15T05:35:58.205720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146077 | REC_0005500 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 11.3 | 56 | male | 1 | 17 | 5.5 | 6 | osimertinib 80 mg daily | 19.7 | false | MSI-H | 2026-03-15T05:35:58.206020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.